Extract
血嗜酸性粒细胞计数(BEC)预测的响应to inhaled corticosteroids (ICS) in COPD patients with increased exacerbation risk [1, 2]. Studies have shown an association between BEC and both sputum and lung tissue eosinophil counts in COPD patients [3, 4], supporting BEC as a biomarker that reflects the degree of eosinophilic lung inflammation. While the long-term stability of BEC in COPD patients has been studied [5–7], the stability of eosinophilic airway inflammation in COPD patients is less clear. Good stability of COPD sputum eosinophil counts up to 3 months has been reported [8, 9], but similar analysis using submucosal eosinophil counts (SMEC) are lacking.
Abstract
Eosinophilic airway inflammation shows greater regional and temporal variability in COPD patients with higher numbers of submucosal eosinophilshttps://bit.ly/3cApnTd
Footnotes
Conflict of interest: A. Higham reports personal fees from Chiesi, outside the submitted work.
Conflict of interest: S. Leow-Dyke has nothing to disclose.
Conflict of interest: N. Jackson has nothing to disclose.
Conflict of interest: D. Singh reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona, outside the submitted work.
Support statement: This research was co-funded by the NIHR Manchester Biomedical Research Centre and the North West Lung Centre Charity, Manchester. This report is independent research and the views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
- ReceivedMarch 10, 2020.
- AcceptedMay 9, 2020.
- Copyright ©ERS 2020